Drugs & Targets GSK and LTZ collaborate to advance novel myeloid cell engagers in oncology November 21, 2025Vol.51 No.43
Drugs & Targets Freenome and Roche to expand collaboration to develop and commercialize cancer screening tests outside the U.S. November 21, 2025Vol.51 No.43
Drugs & Targets Microsoft and Qure.ai collaborate to accelerate AI lung cancer detection November 21, 2025Vol.51 No.43
Conversation with The Cancer LetterRegulatory News Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director November 14, 2025Vol.51 No.42By Paul Goldberg
Regulatory News FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence November 14, 2025Vol.51 No.42By Claire Marie Porter
Trials & Tribulations Smoldering multiple myeloma: Rethinking the waiting game November 14, 2025Vol.51 No.42By C. Ola Landgren
Cancer Policy Trump signs CR that funds government through Jan. 30, ending the longest shutdown in U.S. history November 14, 2025Vol.51 No.42By Jacquelyn Cobb
Cancer Policy Trump administration and Cornell reach agreement to restore federal research funding November 14, 2025Vol.51 No.42By Jacquelyn Cobb and Claire Marie Porter
Cancer Policy CMS announces GENEROUS drug payment model aimed at lowering Medicaid drug prices November 14, 2025Vol.51 No.42By Sara Willa Ernst and Jacquelyn Cobb
